NEW YORK (GenomeWeb) - CombiMatrix reported after the close of the market on Wednesday a 23 percent jump in third quarter revenues.

For the three-month period ended Sept. 30, CombiMatrix's revenues rose to $2.5 million from $2.1 million in the prior-year period.

In a statement, CombiMatrix CEO Mark McDonough said the firm "[continues] to perform and execute on key metrics in terms of driving testing volumes, adding new customers, securing reimbursement contracts, collecting cash, and entering and developing key markets."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.